TABLE 6.

Number of respondents who reported using various pharmacologic therapies for COVID-19–SOT patients categorized by degree of illness

	Mild n = 19 n (%)	Moderate n = 19 n (%)	Critical n = 18 n (%)	Overalla n = 32 n (%)
Anti-inflammatory
Hydroxychloroquineb	10 (52.6)	16 (84.2)	15 (83.3)	25 (78.1)
Interferon alpha	0	0	0	0
Tocilizumabc	0	1 (5.3)	9 (50.0)	10 (31.3)
Pulse steroids	0	0	2 (11.1)	2 (6.3)
Antiviral
Remdesivir	2 (10.5)	4 (21.1)	4 (22.2)	8 (25.0)
Oseltamivir/baloxavir	0	0	0	0
Lopinavir/ritonavir	1 (5.3)	0	3 (16.7)	4 (12.5)
Ribavirin	0	0	0	0
Other agents
Azithromycin	6 (31.6)	9 (47.4)	11 (61.1)	15 (46.9)
Nitazoxanide	0	0	0	0
Start ACEi/ARB	0	0	0	0
Stop ACEi/ARB	0	2 (10.5)	1 (5.6)	2 (6.3)

Note: Respondents could contribute to more than one column (mild, moderate, critical).

^aThis represents the number of individual respondents who reported treating COVID-19–SOT patients; if a respondent contributed to the mild and moderate columns, that respondent would only be counted once in the overall column.

^bIncludes chloroquine.

^cAnti-IL-6.